Anna Grinienko, PharmD

Clinical Trial Leader

Novartis Pharmaceuticals Corporation

One Health Plaza

East Hanover, NJ  07936-1080

 

January 19, 2005

 

Dear Dr. Grinienko,

 

Below are my responses to the questions you asked me to address regarding the lymphoma cases which occurred in patients receiving Elidel cream.

 

As you may know, I am a pathologist with a special interest in lymphomas.  Therefore, my comments will focus on the pathology of these lymphomas.  In addition, I have had the opportunity to study and publish on lymphomas that occur as a result of low-dose, long-term methotrexate therapy for dermatomyositis and rheumatoid arthritis.  I will provide some of the information that has been used to show the causal relationship between lymphoma and methotrexate in that setting.

 

1.      Would additional information be useful in the evaluation of these cases?

 

1)           PHEH2004US01380 – Histiocytic lymphoma

 

                   The tumor immunophenotype and the EBV-status of the tumor cells.

                 

2)           PHEH2004US07674 – Lymphoblastic lymphoma

 

                        No additional information needed.  (This morning, I received the e-mail detailing the clinical history, pathology and immunophenotype of this case)

 

3)           PHBS2004CA12158 – Lymphoma

 

                        There is no information provided for this case.  Clinical, pathologic, immunophenotypic and EBV data would be required to evaluate if this lymphoma occurred as a result of therapy related immune system modulation.

 

4)           PHEH2004US10204 – Subcutaneous panniculitis like T-cell lymphoma

 

                   No additional information is needed.

 

2.      Case Comments

 

1)           PHEH2004US01380 – Histiocytic lymphoma

 

Diffuse large cell lymphoma is one of the most common non-Hodgkin’s lymphomas in adults.  While data regarding immunophenotype and EBV status are not provided, there do not appear to be unusual features (i.e. unusual site, unusual morphology, spontaneous regression). 

 

2)           PHEH2004US07674 – Lymphoblastic lymphoma

 

                        This appears to be a standard case of pediatric lymphoblastic lymphoma. 

 

3)           PHBS2004CA12158 – Lymphoma

 

                   No comments will be provided since there is no information given on this case.

 

4)           PHEH2004US10204 – Subcutaneous panniculitis like T-cell lymphoma

 

                        This is a rare subtype of non-Hodgkin’s lymphoma which to my knowledge has not been associated with iatrogenic immune modulation.

 

3.      Features that Characterize Lymphomas Occurring in the Setting of Immunomodulatory Therapy

 

The literature which first described characteristics of lymphomas occurring as a result of  therapy-related immunosuppression was that describing lymphomas in solid organ transplant recipients.  In the last decade or so, another body of literature has emerged that describes iatrogenic lymphomas associated with immunomodulatory therapy for rheumatologic diseases, in particular rheumatoid arthritis and dermatomyositis (see references below).

 

There are several features which must be present to show a link between immunomodulatory therapy and the development of lymphoma.  This is true for immunosuppression associated lymphomas in solid organ transplants and in iatrogenic lymphomas in patients who receive immunomodulatory therapy for rheumatic diseases.  These features are:

 

1.      Frequent occurrence in unusual sites, including soft tissue, joint spaces, lungs.

2.      Polymorphous, pleomorphic large cell or Hodgkin’s – like morphology.

3.      Presence of Epstein-Barr virus genome in lymphoma cells.

4.      Lymphomas develop weeks, months or less commonly up to several years of receiving immunomodulatory therapy.

5.      In a significant percentage of cases (one-third to one-half), the lymphomas spontaneously regress following withdrawal of immunomodulatory therapy without the need for chemotherapy or radiation therapy.

 

These features, when present in aggregate, implicate therapy as contributing to or causing lymphoma.  Spontaneous regression following discontinuation of therapy is obviously a very important piece of clinical information and was important in linking methotrexate to lymphomas despite the fact that this is an uncommon event.

 

 

4.      Lack of Causal Relationship between administration of Elidel and Lymphoma

 

               None of the information provided indicates or suggests a causal relationship between Elidel and lymphoma. 

 

PHEH2004US01380 – Histiocytic lymphoma

 

I interpret this “histiocytic lymphoma” as representing a diffuse large cell lymphoma using current terminology.  While it would be useful to have data regarding the immunophenotype and EBV status, the description that is provided does not suggest that this lymphoma is immunosuppression related.  This is a relatively common type of lymphoma in older adults.  Its location is not unusual.  No mention is made of an unusual morphology (pleomorphic or Hodgkin’s cell-like).  While the additional data would allow me to be more definitive about this case, none of the information provided indicates a link to immunosuppression.

 

PHEH2004US07674 – Lymphoblastic lymphoma

 

                        This is a straightforward case of pediatric T-lymphoblastic lymphoma.  The additional information provided by e-mail today gives a clinical history typical for this neoplasm, including the mediastinal location.  The T-cell phenotype is typical for this lymphoma in this location in this age group.

 

PHBS2004CA12158 – Lymphoma

 

                   No comments will be provided since there is no information given on this case.

 

PHEH2004US10204 – Subcutaneous panniculitis like T-cell lymphoma

 

                        This is a rare type of non-Hodgkin’s lymphoma that to my knowledge has not been associated with iatrogenic immune modulation.  The clinical, pathologic, and immunophenotypic data that is provided is complete and consistent with a usual presentation, morphology and immunophenotype of this rare type of lymphoma.

 

5.      References

 

1)      Shrioky JB, Frost A, Skelton JD, et al (1991) Complications of immunosuppression associated with weekly  low dose methotrexate.  J Rheumatol 18:  1172 – 1175.

2)      Kingsmore SF, Hall BD, Allen NB, et al (1992)  Association of methotrexate, rheumatoid arthritis and lymphoma:  report of 2 cases and literature review.  J Rheumatol 19:  1462 – 1465.

3)      Kamel OW, van de Rijn M Weiss LM, et al (1993) Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis.  N Engl J Med 328: 1317 – 1321.

4)      Kamel OW, van de Rijn M, Le Brun DP, et al (1994) Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis:  frequency of Epstein-Barr virus and other features associated with immunosuppression.  Hum Pathol 25:  638 – 643.

5)      Salloum E, Cooper DL, Gowe G, et al (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.  J Clin Oncol 14:  1943 – 1949.

6)      Kamel OW, Weiss LM, van de Rijn M, et al (1996) Hodgkin’s disease and lymphoproliferations resembling Hodgkin’s disease in patients receiving long-term, low-dose methotrexate therapy.  Am J Surg Pathol 20:  1279 - 1287.

7)      Kamel OW (1997) Lymphomas during long-term methotrexate therapy.  Arch Dermatol 133:  903 – 904.

8)      Kono H, Inokuma S, Matsuzaki T, et al (1999) Two cases of methotrexate induced lymphomas in rheumatoid arthritis:  and association with increased serum IgE.  J Rheumatol 26: 2249 – 2253.

9)      Kamel OW, Holly EA, van de Rijn M, et al (1999) A population-based case-control study of non-Hodgkin’s lymphoma in patients with rheumatoid arthritis.  J Rheumatol 26:  1176 – 1180.

10)  Kamel OW (2002) Iatrogenic lymphoproliferative disorders in non-transplantation settings.  Recent Results in Cancer Research 159:  19 – 26.

 

 

 

 

Respectfully submitted,

 

 

Onsi W. Kamel, M.D.